UPDATE 1-Novartis contends Roche unjustly enriched itself with $210 mln in fees -lawsuit – Reuters

REUTERS/Arnd WiegmannZURICH (Reuters) – Novartis AG desires Roche Holding AG to return $210 million after accusing its Swiss competitor of wrongly swiping expenses from a 16-year-old patent licensing agreement, according to a lawsuit in U.S. District Court.The disagreement, presented by Novartis in a California state court nevertheless simply recently moved to a federal court, comes from a 2005 offer requiring U.S.-based Chiron Corp to make payments to Roches U.S. Genentech unit for usage of its intellectual property.In 2006, Novartis bought Chiron, a maker of biological drugs and vaccines, and continued making the payments to Roche as it developed products like swelling drug Ilaris, with earnings of roughly $900 million yearly, and psoriasis drug Cosentyx, Novartiss existing leading seller at around $4 billion annual.” Genentech understood or should have know that Novartis had paid excessive … to Genentech throughout the regard to the Agreement,” Novartis legal agents made up.” Genentech has in fact been unjustly improved at Novartiss expenditure,” Novartis lawyers wrote.Reporting by John Miller; Editing by Mark Potter and Bill Berkrot